Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | HCAR3 | P49019 | 2/20 | 0.39 |
| ▸ | BCL6 | P41182 | 1/20 | 0.39 |
| ▸ | BCOR | Q6W2J9 | 1/20 | 0.39 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | KAT2B | Q92831 | 3/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL866327 | 0.91 | MAPT (0.49) | MAPTKDM4EALDH1A1POLBHCAR3 | |
| SCHEMBL864639 | 0.87 | MAPT (0.61) | MAPTKDM4EALDH1A1POLBHCAR3 | |
| SCHEMBL13496368 | 0.85 | MAPT (0.48) | MAPTKDM4EALDH1A1POLBHCAR3 | |
| SCHEMBL1838155 | 0.84 | MAPT (0.50) | MAPTKDM4EALDH1A1HCAR3BCL6 | |
| SCHEMBL1838157 | 0.84 | MAPT (0.50) | MAPTKDM4EALDH1A1HCAR3BCL6 | |
| SCHEMBL864175 | 0.84 | MAPT (0.43) | MAPTKDM4EALDH1A1POLBHCAR3 | |
| SCHEMBL26869713 | 0.83 | KAT2B (0.58) | MAPTKDM4EALDH1A1POLBHCAR3 | |
| SCHEMBL864853 | 0.82 | KDM4E (0.46) | MAPTKDM4EALDH1A1PRSS1GAA | |
| SCHEMBL26870037 | 0.81 | MAPT (0.67) | MAPTKDM4EALDH1A1POLBHCAR3 | |
| SCHEMBL30289547 | 0.80 | MAPT (0.44) | MAPTKDM4EALDH1A1POLBHCAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120077781-A1 | FLAVIN DERIVATIVES | GADWOOD ROBERT (US) | 2012-03-29 | — | — | US | disclosed |
| US-20120077781-A1 | FLAVIN DERIVATIVES | GADWOOD ROBERT (US) | 2012-03-29 | — | — | US | disclosed |
| US-20120077781-A1 | FLAVIN DERIVATIVES | GADWOOD ROBERT (US) | 2012-03-29 | — | — | US | disclosed |
| WO-2010019208-A1 | FLAVIN DERIVATIVES | BIORELIX PHARMACEUTICALS, INC. (US) | 2010-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077781-A1 | FLAVIN DERIVATIVES | BLVRB, FLAD1, FDPS | MAPT 4674/4885KDM4E 1942/4885ALDH1A1 807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.